Company Encyclopedia
View More
name
SPAS
603168.SH
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antimicrobials, gynecology, and other classes. It offers its products in injections, oral solutions, eye drops, tablets, capsules, and other dosage forms.
3.165 T
603168.SHMarket value -Rank by Market Cap -/-

Financial Score

08/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking210/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-3.94%D
    • Profit Margin-13.69%D
    • Gross Margin41.96%B
  • Growth ScoreD
    • Revenue YoY-6.01%D
    • Net Profit YoY23.28%B
    • Total Assets YoY0.64%C
    • Net Assets YoY-4.06%D
  • Cash ScoreD
    • Cash Flow Margin-730.44%E
    • OCF YoY-6.01%D
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreB
    • Gearing Ratio24.08%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SPAS: 49.9215 million shares of non-publicly issued restricted shares will be listed and circulated on November 10

    SPAS announced that 49,921,500 shares of non-publicly issued restricted stock will be listed and circulated on November 10, 2025, accounting for 13.34% of the company's total share capital. The recipients of this issuance are Shanghai Yanghe Industrial Co., Ltd. and Lin Hongyuan. The company was approved for a non-public issuance of shares in 2021 and completed the registration of the new shares in 2022, with a lock-up period of 36 months. The current total share capital of the company is 374,126,505 shares, and the sponsor institution has no objections to the listing and circulation of these restricted shares

    Zhitong·
    SH
    603168
    +1.95%
    Zhitong·
    SH
    603168
    +1.95%

    SPAS released its performance for the first three quarters, with a net profit attributable to shareholders of 27.63 million yuan, turning a profit compared to the same period last year

    According to the Zhitong Finance APP, SPAS disclosed its third-quarter report for 2025. The company achieved revenue of 351 million yuan in the first three quarters, a year-on-year decrease of 2.44%; the net profit attributable to the parent company was 27.63 million yuan, turning from loss to profit year-on-year; the net profit excluding non-recurring gains and losses was 4.32 million yuan, also turning from loss to profit year-on-year; the basic earnings per share were 0.07 yuan

    Zhitong·
    SH
    603168
    +1.95%
    Zhitong·
    SH
    603168
    +1.95%

    Zhitong A-share lock-up release overview | October 27

    On October 27th, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 18.54 billion yuan. The specific situation of the restricted shares unlocked today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares Xiamen Bank 601187 Extended Restricted Lock-up Period Circulation 1.348 billion GZYK 002524 Equity Incentive Restricted Circulation 2.2245 million SPAS 603168 Equity Incentive Restricted Circulation 30,000 Yifeng Pharmacy 603939 Equity Incentive Restricted Circulation 195,000 Jihong Co., Ltd. 002803 Equity Incentive Restricted Circulation 1.98 million Mingyang Circuit 300739 Equity Incentive Restricted Circulation 1.2387 million Arrow Home 001322 Pre-issue Shares Restricted Circulation 800 million Ruichen Environmental Protection 301273 Pre-issue Shares Restricted Circulation 37.0125 million Jinchengzi 688291 6.9 million Wei Ce Technology 688372 270.328 million

    Zhitong·
    SH
    601187
    +3.32%
    SZ
    002524
    +1.54%
    SH
    603939
    -0.94%
    Zhitong·
    SH
    601187
    +3.32%
    SZ
    002524
    +1.54%
    SH
    603939
    -0.94%

    SPAS: The first subject has been enrolled in the Phase III clinical trial of Litanoprost eye drops

    SPAS announced that the Phase III clinical trial of Latanoprost eye drops organized by the company completed the enrollment of the first subject on October 23, 2025. The trial is designed as a multicenter, randomized, double-blind, placebo-controlled study to evaluate its efficacy and safety in treating dry eye in the Chinese population. As of the announcement date, the total R&D investment for this project is approximately 19.1515 million yuan. The drug has a long and complex cycle from clinical trials to production, and the development may be terminated due to various potential issues. The company will disclose progress in a timely manner

    Zhitong·
    SH
    603168
    +1.95%
    Zhitong·
    SH
    603168
    +1.95%

    SPAS: Shanghai Jingxing plans to reduce its holdings by no more than 3%

    According to the Zhitong Finance APP, SPAS announced that Shanghai Jingxing plans to reduce its holdings of the company's shares by no more than 11.2778 million shares, which is no more than 3% of the company's total share capital, within three months from the third trading day after the announcement date, specifically from October 10, 2025, to January 9, 2026

    Zhitong·
    SH
    603168
    +1.95%
    Zhitong·
    SH
    603168
    +1.95%
    © 2025 Longbridge｜Disclaimer